Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats central precocious puberty (CPP). Sold as Supprelin, Vantas, Supprelin La. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 3 applications for Histrelin Acetate (sold as Supprelin, Vantas, Supprelin La), first approved Dec 24, 1991, with 0 new uses approved and 0 published complete response letters.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
